# Option Care Health

> Option Care Health coordinates infusion therapy in homes and ambulatory settings across the United States, combining specialty pharmacy, nursing, nutrition support, insurance coordination and delivery. It served over 315,000 patients in 2025. CD&R and McKesson announced an agreement to acquire it in October 2026; closing remains pending.

- **Founded:** 1979
- **Headquarters:** Bannockburn, United States
- **Founders:** Michael Prime (Co-founder and pharmacist of predecessor Option Care), Mitchell Hoggard (Co-founder and pharmacist of predecessor Option Care)
- **Products:** Home and alternate-site infusion, Anti-infective therapy, Immunoglobulin and specialty therapies, Nutrition support, Patient access and education
- **Notable:** Served over 315,000 patients in 2025., Combined Option Care and BioScrip in August 2019., Reported 13.0% revenue growth in 2025.

## Products & services

- **Home and alternate-site infusion** — Prescribed infusion therapy supported by pharmacists and nurses in homes and ambulatory infusion settings.
- **Anti-infective therapy** — Patient-specific IV antibiotic treatment plans developed with the treating prescriber.
- **Immunoglobulin and specialty therapies** — Infusion support for acute and chronic conditions, including immune and inflammatory disorders.
- **Nutrition support** — Parenteral and enteral nutrition support with clinical care and education.
- **Patient access and education** — Benefits investigation, authorization coordination, financial counseling and treatment education.
- **Biopharma services** — Specialty pharmacy, clinical administration, logistics and patient-support capabilities for manufacturers.

## Achievements

- Served over 315,000 patients in 2025.
- Combined Option Care and BioScrip in August 2019.
- Reported 13.0% revenue growth in 2025.
- January 2026 presentation reported approximately 90 full-service pharmacies, 190+ locations and 750+ infusion chairs.

## Latest updates

- **2026-10** — CD&R and McKesson agreed to acquire the company for $32.05 per share at approximately $5.8 billion enterprise value; pending customary approvals. Option Care Health withdrew its previously disclosed 2026 financial guidance.
- **2026-07** — Q2 revenue reached $1.442 billion, up 1.9%, with net income of $53.9 million, up 6.7%.
- **2026-02** — Reported fiscal 2025 revenue of $5.6495 billion and net income of $207.6 million.
- **2025-08** — Quince selected Option Care Health to support a potential eDSP launch, subject to trial results and approval.

## Links

- Website: https://optioncarehealth.com/
- LinkedIn: https://www.linkedin.com/company/optioncarehealth/
- Twitter/X: https://twitter.com/bioscripinc
- Facebook: https://www.facebook.com/optioncarehealth

---

Profile page: https://yespress.io/option-care-health
Published by YesPress — https://yespress.io
Last updated: 2026-10-22